Archive for the ‘oncology retractions’ Category
Take a look at figure one to the right and see if you can spot all the doubles.
Click here for a more zoomable image.
Here’s the notice for “Effect of ST3GAL 4 and FUT 7 on sialyl Lewis X synthesis and multidrug resistance in human acute myeloid leukemia,” a paper initially published in June: Read the rest of this entry »
A paper by a former postdoc at MD Anderson Cancer Center who “admitted to knowingly and intentionally falsifying” a figure has been retracted.
In August, the Office of Research Integrity announced that it had sanctioned Jun Fu for faking data in a study of the results of a mouse study of NVP-HSP990, a Novartis compound designed to fight brain tumors. Here’s the notice for the study in question, published in Cancer Research:
Read the rest of this entry »
A group of researchers at the Guangdong Academy of Medical Sciences in Guangzhou, China have retracted a paper that came out of a clinical trial on transarterial chemoembolization, a targeted kind of chemotherapy.
According to the notice, one of the authors mixed up the control samples with the clinical samples, and “could not recall which samples were in the wrong group.” The paper hasn’t yet been cited, according to Thomson Scientific’s Web of Knowledge.
Here’s the notice in Medical Oncology:
In June, a paper in Tumor Biology was retracted for at least four reasons, including bad data and hiding a trial sponsor (Merck). Some people who contributed work weren’t cited; at least one author had no idea his name would be on it. And that’s just what they tell us in the notice.
Here’s the notice for “Neutropenia and invasive fungal infection in patients with hematological malignancies treated with chemotherapy: a multicenter, prospective, non-interventional study in China:” Read the rest of this entry »
A cancer paper was retracted on September 17 for a double publication. According to the notice in which the authors admit to duplicating the “opening to the readers,” which we assume is the introduction, there was no need to cite the article “because it had not yet been printed at that time.”
We’ve written before about how common cell line mix ups are in cancer research; according to a 2012 Wall Street Journal article (paywalled), between a fifth and a third of cancer cell lines tested by suspicious researchers turned out to be misidentified.
Obviously, mistakenly studying the wrong kind of cancer is a waste of precious resources, both time and money. And it’s clear the problem hasn’t gone away. PLoS ONE just retracted a cancer paper originally published in December 2012 for studying two cell lines that had been contaminated by other cell types.
Here’s the notice in Cancer Immunology, Immunotherapy for “Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF:” Read the rest of this entry »
The Office of Research Integrity (ORI) has ruled in a case we’ve been following for nearly two years — and which seems to have been launched after Retraction Watch readers took a careful look at figures from what appeared to be an unrelated case.
Takao Takahashi and Makato Suzuki, both former postdocs at a cancer research center at UT-Southwestern, both “knowingly, intentionally, and recklessly falsified data” in a total of 10 papers, according to the ORI. Takahashi, now at Gifu University in Japan, was responsible for fakery in four papers, while Suzuki, now at Kumamoto University Hospital, also in Japan, falsified data in six.
We reported on the retraction of the four Takahashi papers, and one of the Suzuki papers, in November 2012. At that time, Adi Gazdar, the head of the lab where the researchers worked, told us that
Read the rest of this entry »
A few weeks after the paper was published on June 9, comments on PubPeer began accumulating. Commenters called out both potentially manipulated and repeated images. The exact timeline is not clear, because Oncogene does not list a date on the retraction notice, but by August 29 the paper had been retracted.
Here’s the notice for “IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer,” by researchers at Shanghai Jiaotong University School of Medicine and Ruijin Hospital, both in Shanghai, China, and the University of Michigan: Read the rest of this entry »